New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 10, 2012
18:22 EDTINCYIncyte's Jakafi trials suggest survival benefits for patients with myelofibrosis
Incyte Corporation announced that several analyses from clinical studies of Jakafi were presented at the 2012 American Society of Hematology Annual Meeting. Jakafi, an oral Janus kinase, or JAK, inhibitor, is FDA-approved for the treatment of patients with intermediate or high-risk myelofibrosis, or MF. In long-term results from two randomized Phase III clinical trials -- COMFORT-I and COMFORT-II -- patients with myelofibrosis treated with Jakafi had improved survival over placebo and best available therapy, suggesting an overall survival benefit. Additionally, data from an ongoing Phase II trial suggest that long-term treatment with Jakafi may be a durably efficacious therapy for patients with polycythemia vera.
News For INCY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 26, 2015
07:37 EDTINCYIncyte to sponsor U.S. polycythemia vera study
Incyte announced that it is sponsoring the first major observational study of patients living with polycythemia vera in the U.S. PV is a rare and progressive blood cancer that can lead to debilitating symptoms, serious cardiovascular complications, and death.The REVEAL study will seek to describe the real-world clinical burden of PV and how healthcare services are utilized in the management of this disease. Incyte is partnering with approximately 200 community and academic medical centers to conduct the study in the U.S. REVEAL, which recently began enrolling patients, is expected to include 2,000 patients under the supervision of a physician for the active management of PV for a period of three years.
February 23, 2015
07:30 EDTINCYIncyte price target raised to $89 from $75 at Oppenheimer
Oppenheimer increased its price target on Incyte after the company reported that sales of its flagship Jakafi drug had jumped 46% year-over-year in Q4. The firm continues to be upbeat on Jakafi's revenue outlook and the company's pipeline. It keeps an Outperform rating on the shares.
07:06 EDTINCYEli Lilly and Incyte announces positive results for baricitinib
Subscribe for More Information
February 18, 2015
08:13 EDTINCYIncyte shares poised to rise further, says Argus
Subscribe for More Information
February 17, 2015
08:01 EDTINCYIncyte price target raised to $90 from $80 at Leerink
Leerink raised its price target for Incyte shares to $90 citing the company's growing oncology pipeline following its Q4 results. The firm keeps an Outperform rating on the name.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use